Professor Sarfaraz K. Niazi Secures First-Ever FDA Acceptance to Waive Clinical Efficacy Studies for Monoclonal Antibody Biosimilars ...Middle East

PR Newswire - News
Professor Sarfaraz K. Niazi Secures First-Ever FDA Acceptance to Waive Clinical Efficacy Studies for Monoclonal Antibody Biosimilars

CHICAGO, Sept. 1, 2025 /PRNewswire/ -- In a groundbreaking milestone for global healthcare and pharmaceutical innovation, Professor Sarfaraz K. Niazi, Adjunct Professor at the University of Illinois at Chicago and founder of multiple biopharmaceutical enterprises, has secured the...

    Hence then, the article about professor sarfaraz k niazi secures first ever fda acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

    Read More Details
    Finally We wish PressBee provided you with enough information of ( Professor Sarfaraz K. Niazi Secures First-Ever FDA Acceptance to Waive Clinical Efficacy Studies for Monoclonal Antibody Biosimilars )

    Apple Storegoogle play

    Last updated :

    Also on site :

    Most viewed in News